Free Trial

Atea Pharmaceuticals (AVIR) News Today

Atea Pharmaceuticals logo
$2.98 +0.09 (+2.93%)
As of 01:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AVIR Latest News

Atea Pharmaceuticals (NASDAQ:AVIR) Upgraded at Wall Street Zen
Atea Pharmaceuticals, Inc. stock logo
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Holdings Increased by Tang Capital Management LLC
Tang Capital Management LLC grew its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 3.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,788,912 shares of the company's stoc
Atea Pharmaceuticals, Inc. stock logo
Jacobs Levy Equity Management Inc. Lowers Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
Jacobs Levy Equity Management Inc. decreased its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 23.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 390,899 shares of t
William Blair Issues Pessimistic Estimate for AVIR Earnings
Atea Pharmaceuticals, Inc. stock logo
Newtyn Management LLC Purchases 200,000 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
Newtyn Management LLC boosted its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 52.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 580,000 shares of the company's stock after buying an additional 200,000 share
Atea Pharmaceuticals, Inc. stock logo
Dimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
Dimensional Fund Advisors LP increased its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 23.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 977,470 shares of the company's stock
Atea Pharmaceuticals, Inc. stock logo
Atea Pharmaceuticals (NASDAQ:AVIR) Issues Earnings Results, Beats Expectations By $0.01 EPS
Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) released its earnings results on Monday. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.01.
Atea Pharmaceuticals, Inc. stock logo
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Monday
Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-atea-pharmaceuticals-inc-stock/)
Atea Pharmaceuticals, Inc. stock logo
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stake Lessened by Almitas Capital LLC
Almitas Capital LLC trimmed its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 45.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 752,003 shares of the company's stock after selling 632,526 sh
Atea Pharmaceuticals, Inc. stock logo
JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
JPMorgan Chase & Co. increased its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 329.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 409,259 shares of the company's sto
Atea Pharmaceuticals, Inc. stock logo
RBF Capital LLC Has $183,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
RBF Capital LLC cut its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 63.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 54,929 shares of the company's stock after selling 93,522 shares dur
Atea Pharmaceuticals, Inc. stock logo
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. decreased its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 3.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,666,854 shares of the company's stock afte
Morgan Stanley Remains a Hold on Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals, Inc. stock logo
Morgan Stanley Has Lowered Expectations for Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price
Morgan Stanley lowered their target price on Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating on the stock in a research note on Friday.
Atea Pharmaceuticals, Inc. stock logo
ADAR1 Capital Management LLC Invests $368,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
ADAR1 Capital Management LLC bought a new stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 110,000 shares of the company's
Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory
Atea Pharmaceuticals, Inc. stock logo
What is William Blair's Forecast for AVIR Q1 Earnings?
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Atea Pharmaceuticals in a report issued on Friday, March 7th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.40) fo
Atea Pharmaceuticals, Inc. stock logo
Atea Pharmaceuticals (NASDAQ:AVIR) Receives "Outperform" Rating from William Blair
William Blair reissued an "outperform" rating on shares of Atea Pharmaceuticals in a research report on Friday.
Atea Pharmaceuticals, Inc. stock logo
BML Capital Management LLC Has $25.49 Million Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
BML Capital Management LLC lifted its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 14.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,608,312 shares of the company's s
Atea Pharmaceuticals, Inc. stock logo
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Quarterly Earnings Results
Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05).
Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)
Atea Pharmaceuticals, Inc. stock logo
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday
Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.
Atea Pharmaceuticals, Inc. stock logo
Atea Pharmaceuticals (AVIR) Expected to Announce Earnings on Wednesday
Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing earnings before the market opens on Wednesday, February 26.
Get Atea Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.

AVIR Media Mentions By Week

AVIR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AVIR
News Sentiment

1.13

0.78

Average
Medical
News Sentiment

AVIR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AVIR Articles
This Week

1

2

AVIR Articles
Average Week

Get Atea Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:AVIR) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners